Analyses are solely the work of the authors and have not been edited or endorsed by GLG.
Positive and Highly Significant Phase III Results
September 13, 2009
Nitec Pharma Reports Positive and Highly Significant Phase III Results From Capra-2 Study of Lodotra(TM) in RA | www.pipelinereview.com
Nitec Pharma, a Switzerland-based specialty pharma company focused on the development and commercialization of medicines to treat chronic inflammation and pain-related diseases, today announced positive results from the second pivotal phase III trial for its lead product, Lodotra.
PHOSPHAGENICS TO COMMENCE PHASE 2/3 TOPICAL DICLOFENAC TRIAL
September 12, 2009
PHOSPHAGENICS TO COMMENCE PHASE 2/3 TOPICAL DICLOFENAC TRIAL | www.pipelinereview.com
Progression to the next step of clinical trials for topical NSAID - Diclofenac.
June 10, 2009
FDA Approves SBi's S.T.A.R. Total Ankle Replacement System | www.medicalnewstoday.com
While mobile-bearing total ankle replacement systems have a promising track record in Europe, to date all the the FDA-approved total ankle systems in the United States have been fixed-bearing. This system is the first mobile-bearing device to receive FDA approval.
April 29, 2009
Efficacy and safety of balloon kyphoplasty compared with non-surgical care for vertebral compression fracture (FREE): a randomised controlled trial. | linkinghub.elsevier.com.ezproxy.its.uu.se
This article helps validate Kyphoplasty from the European front. It does not, however, have direct translation from a financial standpoint beacuse there are vast differences in healthcare funding from Eurpo to the US.
April 20, 2009
Efficacy and safety of balloon kyphoplasty compared with non-surgical care for vertebral compression fracture (FREE): a randomised controlled trial. | linkinghub.elsevier.com.ezproxy.its.uu.se
The results of the FREE-study encourage the use of kyphoplasty to stabilize osteoporotic compression fractures, and will have major impact on reimbursement of kyphoplasty in Europe and the rest of the world. Already after 1 month pain (VAS), Quality of Life (EQ5D), and function (SF-36) is significantly improved, if kyphoplasty is used to stabilize osteoporotic vertebral compression fractures, which is pertained during one year followup.
My experience as a Primary Care provider
April 20, 2009
Efficacy and safety of balloon kyphoplasty compared with non-surgical care for vertebral compression fracture (FREE): a randomised controlled trial. | linkinghub.elsevier.com.ezproxy.its.uu.se
We are quite fortunate to have several orthopods who do this procedure at our Yale affiliated teaching hospital. We have had Grand Rounds on this procedure (intended to "sell" us on the concept) and I have had 2 office details by Reps in the past from Kyphon. I just had a recent case of a 92 year woman with 2 vertebral fractures who got relief in 2-3 days, but has now had problems with a shifted "X-Stop" device she is scheduled to have removed soon.
March 12, 2009
Hip deals put money in pocket | www.chicagotribune.com
The link between consultants and industry should not be stifled, lest it choke off innovation. However, accepting payment to buy loyalty to one product or drug probably goes too far.
March 10, 2009
Hip deals put money in pocket | www.chicagotribune.com
This article is a liberal attempt to marginalize the changes in Orthopedic protocol. The practices of each individual physician would need to be analyzed to truly apply these very broad statements. People fail to give surgeons proper credit for implant selection and their "unspoken" code of ethics.
AZX100: an HSP20 mimic for smooth muscle relaxation in keloid myofibroblasts
February 13, 2009
Capstone Therapeutics Announces Initiation of Dosing for AZX100 Phase 2 Clinical Trial in Dermal Scarring; Management to Host Teleconference and Webcast Today | www.msnbc.msn.com
AZX100 from Capstone Therapeutics is a cell-permeable peptide meant to mimic HSP20 and its ability to relax smooth muscle actin, a feature of myofibroblasts in wounds. Keloids form because of a hyper-responsive positive loop of TGFbeta expression. A lack of ability to limit this loop creates a hyper-cellular tissue with high cell/matrix turnover. Tension has been implicated as a factor in myofibroblast physiology and phenotype. The question will be whether release of tension in these cells will be sufficient to advance the process beyond the myofibroblast toward stable repair.
February 11, 2009
Capstone Therapeutics Announces Initiation of Dosing for AZX100 Phase 2 Clinical Trial in Dermal Scarring; Management to Host Teleconference and Webcast Today | www.msnbc.msn.com
YEARS OF DOING SKIN SURGERY, TREATING KELOIDS IN PATIENTS HAVE DEMONSTRATED A NEED FOR A KELOID PREVENTING MODALITY. AZX100 SHOULD BE STUDIED, IF IT HAS NOT ALREADY BEEN, IN PATIENTS PRONE TO KEOIDS WHO NEED FURTHER SKIN SURGERY. THIS GIVE US AN EXCELLENT REPRODUCIBLE CLINICAL MODEL WITH A VISIBLE AND CONTROLLED END POINT.
What is potential future for Sequenom in prenatal testing.
November 9, 2009
November 7, 2009
Express Scripts feeling Growing Pains
October 29, 2009
CDC Outlines H1N1 Test Guidelines
October 8, 2009
Why Health Care Costs Keep Rising—And What to Do About It
September 13, 2009